Commandré F A, Fornaris E, Fourré J M, Raybaud A, Colonna P, Pirdas C
Sem Hop. 1983 Dec 12;59(46):3249-53.
Effectiveness and tolerance of ketoprofen in sustained-release tablets (Bi-Profenid 150 mg) were investigated in a double blind trial in 44 athletes who had recently sprained an ankle. Patients were given either 300 mg Bi-Profenid or 400 mg oxyphenbutazone daily for seven days. Treatment regimens were assigned at random. Results were assessed as excellent or good in 85% of patients given Bi-Profenid and 50% of those given oxyphenbutazone. Spontaneous pain resolved in 19 patients receiving Bi-Profenid and in 6 under oxyphenbutazone. Decrease in pain upon physical examination and in articular circumference was significantly greater with Bi-Profenid as compared with oxyphenbutazone. The chance of rapidly resuming sport was better with Bi-Profenid. Tolerance was excellent in 68.2% of patients with Bi-Profenid and 59% of those with oxyphenbutazone. This investigation thus emphasizes the value of Bi-Profenid in sport pathology.
在一项双盲试验中，对44名近期脚踝扭伤的运动员研究了酮洛芬缓释片（必普洛芬150毫克）的有效性和耐受性。患者被随机分配，每日服用300毫克必普洛芬或400毫克奥沙普秦，为期7天。接受必普洛芬治疗的患者中85%的结果评估为优或良，接受奥沙普秦治疗的患者中这一比例为50%。19名服用必普洛芬的患者和6名服用奥沙普秦的患者自发疼痛得到缓解。与奥沙普秦相比，必普洛芬使体检时疼痛和关节周长的减小更为显著。服用必普洛芬后迅速恢复运动的可能性更大。服用必普洛芬的患者中68.2%耐受性良好，服用奥沙普秦的患者中这一比例为59%。因此，本研究强调了必普洛芬在运动病理学中的价值。
